Table 2 Comparison of the characteristics of CCP^a population with ICH^b according to sex

Age (years)

83.6 [9.1]

88.9 [7.7]

< 0.001

  < 80 years

72.1 [6.9]

72.6 [7.0]

0.861

  ≥ 80 years

87.8 [5.5]

90.7 [5.3]

0.003

 Arterial hypertension

60 (84.5)

74 (82.2)

0.700

 Diabetes

30 (42.3)

28 (31.1)

0.144

 Hypercholesterolemia

31 (43.7)

58 (64.4)

0.008

 Cardiovascular disease

35 (49.3)

24 (26.7)

0.003

 Ischemic cardiopathy

22 (31.0)

11 (12.2)

0.003

 Ischemic stroke/Transient ischemic accident

8 (11.3)

8 (8.9)

0.616

 Peripheral artery disease

8 (11.3)

9 (10.0)

0.795

 Atrial fibrillation

17 (23.9)

34 (37.8)

0.061

 Heart failure

13 (18.3)

21 (23.3)

0.438

 Thromboembolism

4 (5.6)

9 (10.0)

0.313

 Chronic kidney disease

24 (33.8)

12 (13.3)

0.002

 Chronic liver disease

1 (1.4)

0 (0.0)

0.259

 Institutionalized

2 (2.8)

7 (7.8)

0.174

 Record of previous falls

5 (7.0)

16 (17.8)

0.045

 Cognitive impairment or dementia

13 (18.3)

25 (27.8)

0.160

 Alcohol consumption

14 (19.7)

5 (5.6)

0.006

 Bleeding predisposition

10 (14.1)

3 (3.3)

0.013

 Systolic blood pressure (mmHg)

134.7 [12.2]

131.3 [14.3]

0.096

 Glycosylated haemoglobin A1c (%)

6.6 [1.5]

6.1 [1.3]

0.039

 Glomerular filtration rate (mL/min/1.73m²)

66.9 [25.3]

65.9 [16.7]

1.000

 CHA₂DS₂-VASC score

3 [0.00]

5.5 [0.7]

0.102

 HAS-BLED score

3.7 [1.0]

3.3 [0.7]

0.014

 Barthel index

70.3 [23.7]

75.6 [24.7]

0.145

 Oral anticoagulant (VKA^c o NOAC^d)

22 (31.0)

32 (35.6)

0.542

 NOAC^d

2.0 (2.8)

1.0 (1.1)

0.427

 NSAID^e

49 (69.0)

63 (70.0)

0.893

 Antiplatelet drugs

54 (76.1)

49 (54.4)

0.005

 Statin

37 (52.1)

48 (53.3)

0.878

 SSRI^f

17 (23.9)

42 (46.7)

0.003

 PPI^g

62 (87.3)

74 (82.2)

0.375